AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: See arm description
Study NCT02912598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fuji Uniblocker™
Study NCT03098368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of rotigotine patch
Study NCT01017146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene foam
Description: Tazarotene foam once a day application to the face
Study NCT02912598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight™-SL+EB
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: See arm description
Study NCT03041935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: See arm description
Study NCT00882024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: 150 mg tranilast tablets, bid, 12 weeks
Study NCT00882024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: 75 mg tablets, bid, 12 weeks
Study NCT00882024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, bid, 12 weeks
Study NCT00947128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
Study NCT00947128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
Study NCT01010607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration and Mirror
Description: 10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
Study NCT01010607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: 10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
Study NCT01010607 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: no mirror, sham vibration
Description: 10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
Study NCT02605408 — intervention group
Intervention type: DEVICE
Intervention: LenSx® laser system
Description: Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
Study NCT02605408 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification
Description: Removal of the cataractous lens
Study NCT03381287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801 Tablets, 500 mg
Description: 500 mg/day (250 mg BID)
Study NCT03381287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801 Tablets, 1000 mg
Description: 1000 mg/day (500 mg BID)
Study NCT03381287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801 Tablets, 2000 mg
Description: 2000 mg/day (1000 mg BID)
Study NCT03381287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match 500 mg HTD1801
Description: 2 tablets/day (1 tablet BID)
Study NCT04119544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
Study NCT02912598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COOK© Arndt Endobronchial Blocker
Study NCT04083898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab will be administered on a 28-day cycle
Study NCT03381287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match 1000 mg HTD1801
Description: 4 tablets/day (2 tablet BID)
Study NCT03381287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match 2000 mg HTD1801
Description: 8 tablets/day (4 tablet BID)
Study NCT03744338 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest.
Study NCT00207220 — intervention group
Intervention type: PROCEDURE
Intervention: arterial tonometry
Description: used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
Study NCT00207220 — intervention group
Intervention type: PROCEDURE
Intervention: echocardiography
Description: ultrasound test using sound waves to create a moving picture of the heart
Study NCT04083898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered on a 28-day cycle as follows
Study NCT04083898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered on a 28-day cycle as follows
Study NCT04119544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Visual Simulation
Description: * First week: observation, mentalization and then attempt to perform the movements on the screen.~* Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~* From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
Study NCT03471520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Description: Patients in this study will be given earplugs and eye masks to be worn during sleep
Study NCT03727230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients
Study NCT01812486 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose de escalation
Study NCT01812486 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard dose
Study NCT04545788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
Description: AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
Study NCT04545788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
Description: AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
Study NCT03372629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID-085
Description: Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
Study NCT03372629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules matching ID-085 capsules
Study NCT01780909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate Fasted State
Study NCT01780909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate Fed State
Study NCT03214146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYNRCS-Allo inj
Description: The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\^6 cells/kg according to the protocol design.
Study NCT01017146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam once a day application to the face
Study NCT03739593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-1105-CF1
Description: AR-1105 clinical formulation 1 (AR-1105-CF1)
Study NCT03739593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-1105-CF2
Description: AR-1105 clinical formulation 2 (AR-1105-CF2)
Study NCT01780909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate w/ domperidone
Study NCT01780909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin Sulfate w/ loperamide HCl
Study NCT00715312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Olein
Description: A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
Study NCT00715312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Olein
Description: A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
Study NCT03536598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg
Study NCT03536598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg + Valsartan 160 mg
Study NCT03536598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg + Rosuvastatin 20 mg
Study NCT02573376 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Directly Observed Therapy
Study NCT02573376 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wirelessly Observed Therapy
Study NCT03372473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast mixed with Loratadine
Description: Montelukast 5mg mixed with Loratadine 5mg, one dose per day
Study NCT03372473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 5mg
Study NCT05798273 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intra-arterial injection
Description: All patients will receive an intravenous injection of \[68Ga\]Ga-PSMA-11 (1.5 MBq/kg), followed by a synchronous PET/MRI scan (median duration approximately 50 min) at 45-60 min post-injection.~In case of a positive \[68Ga\]Ga-PSMA-PET signal at the tumor site, patients will return (in 2 weeks) for an intra-arterial injection (i.e., a neuro-interventional procedure) of 68Ga-PSMA-11 (1.5 MBq/kg), followed by a repeat synchronous PET/MRI scan (median duration 50 min) at 45-60 min post-injection.
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 50 mg/m2
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2
Study NCT05798273 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: synchronous PET/MRI scan
Description: Scan done at (median duration approximately 50 min) at 45-60 min post-injection.
Study NCT05798273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radiopharmacon Contrast agent
Description: Type: \[68Ga\]Ga-PSMA-11 dosage: 1.5 MBq/kg
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 625 mg/m2
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 200 mg/m2
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 200 mg/m2
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 2 mg/ml min
Study NCT02022072 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
Description: measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
Study NCT02287129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2
Study NCT02287129 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: total dosage 41,4 Gy
Study NCT02287129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: translational analysis
Study NCT00261807 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daptomycin 6mg/kg/day
Study NCT04568044 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Peripheral blood sample will be obtained.
Study NCT02548416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive end-expiratory pressure
Description: Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
Study NCT02548416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group, zero PEEP
Description: Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
Study NCT03857893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Quadripolar Radio-Frequency treatment
Description: Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology.
Study NCT03857893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pH-Cream
Description: 1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
Study NCT03857893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pH-Cream
Description: 1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
Study NCT04944329 — intervention group
Intervention type: PROCEDURE
Intervention: Hip fracture surgery
Description: Hip fracture surgery
Study NCT01031485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk peptides and plant sterols
Study NCT01031485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02090985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipomodelling of symptomatic peri-stomal skin contour abnormalities
Study NCT04312204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab combined with Gemcitabine and Carboplatin
Description: The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months.
Study NCT02966262 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography
Description: Intracoronary imaging device which can precisely observe intracoronary structures
Study NCT05199181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy
Description: After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
Study NCT04044378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: famitinib with RP2D orally daily
Study NCT04044378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famitinib
Description: famitinib with RP2D orally daily
Study NCT04044378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
Study NCT04044378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: camrelizumab 200mg infusion once Q2W
Study NCT02252913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: oral administration
Study NCT02287129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: translational analysis
Study NCT03443193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
Study NCT03945032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TICOP
Description: Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
Study NCT02494778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pridopidine
Description: 45 mg BID
Study NCT00825019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amibegron (SR58611A)
Description: oral administration of 2x 700 mg/day in 12h intervals
Study NCT00825019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration in 12h intervals
Study NCT02252913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous injection
Study NCT02926781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dask Advanced Sinus kit
Description: a kit of specially designed drills for closed sinus lift
Study NCT00825019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: oral administration of 20 mg/day
Study NCT01539278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Description: Tonsils and adenoids are surgically removed
Study NCT02926781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dask Advanced Sinus kit
Description: a kit of specially designed drills for closed sinus lift